Sandell Asset Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Sandell Asset Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-200,000	Closed	-$9.6M	–	70
2020 Q1	$9.6M	Buy	+200,000	New	+$9.3M	2.09%	13

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Sandell Asset Management's RARX Position: Q2 2020 in Review

Sandell Asset Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 200,000 shares — an estimated $9.6M sold.

Sandell Asset Management first reported a position in RARX in Q1 2020 and held it in 1 quarter. The position peaked at $9.6M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Sandell Asset Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Sandell Asset Management sold 200,000 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $9.6M.
Sandell Asset Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
Sandell Asset Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $9.6M in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Sandell Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.